[
    {
        "question": "A large gene has dozens of exons, of which the central ones code for folded triple helical repeats that connect the cytoskeleton with sarcolemma and extracellular space. Each exon usually codes for one folded triple alpha helix. The most common mutations of the gene are central exon deletions that create out-of-frame peptides and progressive degenerative organ waste. A solution is to deliver a Morpholino that recognizes the 5' end of the out-of-frame exon in pre-mRNA. The molecule prevents binding of the spliceosome and creates exon skipping and in-frame joining. Several missing exons are well tolerated by an organism. Which structure below is not involved in the proposed therapy?",
        "label_A": "polyA tail",
        "label_B": "lariat",
        "label_C": "antisense",
        "label_D": "R-loops",
        "answer": "D",
        "Subdomain": "Molecular Biology",
        "High-level domain": "Biology",
        "generated_text": "<think>\nOkay, let's try to figure out this question. So, the question is about a gene therapy approach using Morpholino to skip exons and correct a frameshift caused by exon deletions. The question asks which structure is not involved in this therapy.\n\nFirst, let me recap the context. The gene has many exons, each coding for a triple helix. Mutations involve deleting central exons, leading to out-of-frame peptides and disease. The solution is to use a Morpholino that binds to the 5' end of the out-of-frame exon in pre-mRNA. This prevents the spliceosome from binding, causing the exon to be skipped, and the remaining exons to join in-frame. The organism can tolerate missing some exons.\n\nNow, the answer choices are A: polyA tail, B: lariat, C: antisense, D: R-loops.\n\nLet me think about each option and how they relate to the therapy described.\n\nA: polyA tail. The polyA tail is added to the 3' end of mRNA after splicing. It's part of mRNA processing but not directly involved in splicing itself. The therapy is about splicing, so maybe the polyA tail isn't involved here.\n\nB: lariat. Spliceosomes create a lariat structure during splicing when introns are removed. If the Morpholino prevents the spliceosome from binding, then the lariat formation might be affected. So the lariat is part of the normal splicing process, which is being altered here. So it's involved in the normal process but not directly in the therapy. But the question is whether it's involved in the proposed therapy. The therapy is about preventing splicing at that exon, so maybe the lariat isn't formed for that exon anymore. But the lariat is part of the splicing mechanism that's being blocked. So maybe the lariat is related to the therapy's mechanism.\n\nC: antisense. Morpholino is an antisense oligonucleotide because it binds to a specific sequence in the pre-mRNA (antisense means it's complementary to the target RNA). So antisense technology is directly involved in the therapy. So option C is involved.\n\nD: R-loops. R-loops are three-stranded structures formed when an RNA hybridizes with one DNA strand, displacing the other DNA strand. They are usually formed during transcription or DNA replication. I don't think R-loops are directly involved in splicing or the action of Morpholino in this context. The Morpholino binds to RNA, but R-loops are a different phenomenon. Unless the Morpholino somehow causes R-loops, but that's not mentioned here. So maybe D is not involved.\n\nSo the question is which structure is not involved. The therapy uses antisense (C) to block splicing. The normal splicing process involves lariat (B) formation. The polyA tail (A) is part of mRNA processing but not directly involved in splicing. R-loops (D) are not related to splicing or the therapy described.\n\nSo the answer would be either A or D. Let me think again.\n\nThe polyA tail is added after splicing, but the therapy is about splicing. The polyA tail isn't directly involved in the splicing process or the exon skipping. The Morpholino doesn't affect the polyA tail. So A is not involved.\n\nR-loops are not part of the splicing process. So D is also not involved. But the question asks which is not involved in the proposed therapy. The answer choices are A, B, C, D. The therapy uses antisense (C) which is involved. Lariat (B) is part of normal splicing, but the therapy is preventing splicing at that exon, so lariat formation for that exon is prevented. But the question is about structures involved in the therapy. The lariat is part of the normal process, not the therapy. The therapy is using antisense to block splicing. So the lariat isn't part of the therapy. But the question is which is not involved in the proposed therapy. So if the therapy doesn't involve lariat formation, then B is not involved. But the question is about which structure is not involved in the therapy. The therapy is about preventing splicing, so the lariat isn't formed. But the lariat is a byproduct of splicing. Since the therapy is preventing splicing, the lariat isn't formed. So the lariat is not part of the therapy's mechanism. But the question is which structure is not involved in the proposed therapy. So the answer would be A, B, or D.\n\nLet me think again. The therapy uses antisense (C) to block splicing. So C is involved. The other options: polyA tail (A) is part of mRNA processing but not directly involved in splicing. Lariat (B) is part of splicing. R-loops (D) are not related to splicing. So the answer is either A or D. Which one is not involved in the therapy.\n\nThe therapy is about splicing, so lariat (B) is part of the normal splicing process, but the therapy is preventing that. The polyA tail is added after splicing. The therapy doesn't affect the polyA tail. R-loops are not part of splicing. So the answer is D: R-loops. Because the therapy doesn't involve R-loops. The polyA tail is part of mRNA processing but not directly involved in the splicing therapy. But the question is which is not involved in the proposed therapy. The polyA tail is part of the mRNA processing, but the therapy is about splicing. The polyA tail isn't directly involved in the therapy. But the question is about structures involved in the therapy. The therapy doesn't involve the polyA tail. So A is not involved. But the answer choices are A, B, C, D. The correct answer is either A or D.\n\nWait, the question is which structure is not involved in the proposed therapy. The therapy uses antisense (C) to block splicing. The lariat (B) is part of the normal splicing process, but the therapy is preventing that. The polyA tail (A) is added after splicing. The R-loops (D) are not related to splicing. So the answer is D: R-loops. Because the therapy doesn't involve R-loops. The polyA tail is part of mRNA processing but not directly involved in the splicing therapy. But the question is about which is not involved in the therapy. The polyA tail is not part of the therapy. But the answer choices are A and D. Which one is correct?\n\nThe question is about the structures involved in the proposed therapy. The therapy is about splicing. The polyA tail is added after splicing. The therapy doesn't affect the polyA tail. The R-loops are not part of splicing. So the answer is D: R-loops. Because the therapy doesn't involve R-loops. The polyA tail is part of mRNA processing but not directly involved in the splicing therapy. But the question is about which is not involved in the proposed therapy. The answer is D.\n</think>\n\nD",
        "prediction": "D",
        "is_correct": true,
        "output_tkn": 1513,
        "repredicted": false
    },
    {
        "question": "Two quantum states with energies E1 and E2 have a lifetime of 10^-9 sec and 10^-8 sec, respectively. We want to clearly distinguish these two energy levels. Which one of the following options could be their energy difference so that they can be clearly resolved?\n",
        "label_A": "10^-9 eV",
        "label_B": "10^-8 eV\n",
        "label_C": "10^-4 eV",
        "label_D": "10^-11 eV",
        "answer": "C",
        "Subdomain": "Physics (general)",
        "High-level domain": "Physics",
        "generated_text": "<think>\nOkay, let's try to figure this out. The question is about two quantum states with different energies and lifetimes. We need to find the energy difference that allows them to be clearly distinguished.\n\nFirst, I remember that in quantum mechanics, there's the Heisenberg uncertainty principle which relates the uncertainty in energy and the lifetime of a state. The formula is ΔE * Δt ≥ ħ/2, where ΔE is the uncertainty in energy and Δt is the lifetime. So each state has an energy uncertainty inversely proportional to its lifetime.\n\nThe two states have lifetimes of 10^-9 seconds and 10^-8 seconds. Let's calculate their energy uncertainties. For the first state with Δt1 = 10^-9 s, the uncertainty ΔE1 would be approximately ħ / Δt1. Similarly for the second state with Δt2 = 10^-8 s, ΔE2 ≈ ħ / Δt2. \n\nSince ħ is the reduced Planck constant, which is about 1.0545718 × 10^-34 J·s. But since we're dealing with electron volts (eV), maybe I should convert that. 1 eV is 1.602 × 10^-19 J. So ħ in eV·s is roughly 6.582 × 10^-16 eV·s. \n\nCalculating ΔE1: ħ / 10^-9 s = 6.582e-16 eV·s / 1e-9 s = 6.582e-7 eV. So about 6.58 × 10^-7 eV. \n\nFor ΔE2: ħ / 1e-8 s = 6.582e-16 / 1e-8 = 6.582e-8 eV. Approximately 6.58 × 10^-8 eV.\n\nThe total uncertainty when considering both states would be the sum of these two uncertainties? Or maybe we need to consider the combined uncertainty for resolving the two levels. To clearly distinguish the two energy levels, the energy difference between them should be larger than the sum of their individual uncertainties. \n\nSo the total uncertainty ΔE_total = ΔE1 + ΔE2 ≈ 6.58e-7 + 6.58e-8 = approx 7.24e-7 eV. \n\nTherefore, the energy difference between E1 and E2 must be greater than this total uncertainty to be clearly resolved. Let's look at the answer choices:\n\nA: 1e-9 eV (which is 0.001e-6 eV) – way smaller than 7.24e-7 eV. Not good.\n\nB: 1e-8 eV (0.1e-7 eV) – still smaller than 7.24e-7 eV. Not enough.\n\nC: 1e-4 eV (0.0001 eV) – which is 1e-4 eV = 1e-4 eV. Comparing to 7.24e-7 eV, this is much larger. So this would be sufficient.\n\nD: 1e-11 eV – way too small.\n\nSo the correct answer should be C: 10^-4 eV. That's much larger than the combined energy uncertainties, allowing the two levels to be clearly resolved.\n</think>\n\nC",
        "prediction": "C",
        "is_correct": true,
        "output_tkn": 761,
        "repredicted": false
    },
    {
        "question": "trans-cinnamaldehyde was treated with methylmagnesium bromide, forming product 1.\n\n1 was treated with pyridinium chlorochromate, forming product 2.\n\n3 was treated with (dimethyl(oxo)-l6-sulfaneylidene)methane in DMSO at elevated temperature, forming product 3.\n\nhow many carbon atoms are there in product 3?",
        "label_A": "10",
        "label_B": "14",
        "label_C": "12",
        "label_D": "11",
        "answer": "D",
        "Subdomain": "Organic Chemistry",
        "High-level domain": "Chemistry",
        "generated_text": "<think>\nOkay, let's try to figure out how many carbon atoms are in product 3. The question involves a series of chemical reactions starting with trans-cinnamaldehyde. Let me break it down step by step.\n\nFirst, trans-cinnamaldehyde has the structure of a benzene ring attached to a carbon-carbon double bond (C=C) and an aldehyde group (CHO). The molecular formula for trans-cinnamaldehyde is C9H8O. So, there are 9 carbon atoms in the starting material.\n\nThe first reaction is with methylmagnesium bromide, which is a Grignard reagent. Grignard reagents typically react with aldehydes to form alcohols. Specifically, when a Grignard reagent (RMgX) reacts with an aldehyde (R'CHO), it forms a secondary alcohol (RCH(R')OH) after hydrolysis. \n\nIn this case, methylmagnesium bromide (CH3MgBr) reacting with trans-cinnamaldehyde (which has the aldehyde group) would add a methyl group to the aldehyde carbon. The aldehyde has one R group (the styryl group from cinnamaldehyde) and the Grignard adds another methyl group. So the product 1 would be a secondary alcohol. The carbon count here would be the original 9 carbons from cinnamaldehyde plus 1 from the methyl group, totaling 10 carbons in product 1.\n\nNext, product 1 is treated with pyridinium chlorochromate (PCC). PCC is an oxidizing agent that typically oxidizes alcohols. For secondary alcohols, PCC converts them into ketones. So product 2 would be a ketone. The carbon count here remains the same as product 1, which is 10 carbons, because oxidation doesn't add or remove carbon atoms—it just changes the functional group.\n\nNow, product 3 is formed by treating product 2 with (dimethyl(oxo)-l6-sulfaneylidene)methane in DMSO at elevated temperature. This part is a bit tricky. The reagent mentioned is a bit obscure, but the key part is \"dimethyl(oxo)-l6-sulfaneylidene)methane.\" Let me try to parse that.\n\nThe term \"sulfaneylidene\" suggests a sulfur-containing group. The \"dimethyl(oxo)\" part might indicate that there's a carbonyl group (oxo) and two methyl groups attached to the sulfur. The structure might be something like a sulfur ylide or a related compound. However, without the exact structure, it's challenging to be certain. But perhaps this reagent is involved in a carbon-carbon bond-forming reaction.\n\nAssuming that this reagent is adding two methyl groups (each with one carbon) to product 2, then product 3 would have 10 + 2 = 12 carbons. Alternatively, if the reaction involves some kind of condensation or elimination that doesn't add carbons, the count might stay the same. But given that the reagent has \"dimethyl\" in its name, it's plausible that two methyl groups are involved in the reaction.\n\nTherefore, product 3 would have 12 carbon atoms. The answer would be C: 12.\n</think>\n\nC",
        "prediction": "C",
        "is_correct": false,
        "output_tkn": 708,
        "repredicted": false
    }
]